Extremal loop weight modules and tensor products for quantum toroidal algebras

We define integrable representations of quantum toroidal algebras of type A by tensor product, using the Drinfeld "coproduct". This allow us to recover the vector representations recently introduced by Feigin-Jimbo-Miwa-Mukhin [6] and constructed by the author [21] as a subfamily of extremal loop weight modules. In addition we get new extremal loop weight modules as subquotients of tensor powers of vector representations. As an application we obtain finite-dimensional representations of quantum toroidal algebras by specializing the quantum parameter at roots of unity.Comment: 30 page

Preordered forests, packed words and contraction algebras

We introduce the notions of preordered and heap-preordered forests, generalizing the construction of ordered and heap-ordered forests. We prove that the algebras of preordered and heap-preordered forests are Hopf for the cut coproduct, and we construct a Hopf morphism to the Hopf algebra of packed words. Moreover, we define another coproduct on the preordered forests given by the contraction of edges. Finally, we give a combinatorial description of morphims defined on Hopf algebras of forests with values in the Hopf algebras of shuffes or quasi-shuffles.Comment: 42 pages. arXiv admin note: text overlap with arXiv:1007.1547, arXiv:1004.5208 by other author

Prix Nobel de Chimie 2005 : Yves Chauvin, Robert H. Grubbs et Richard R. Schrock. Métathèse et catalyse à l’honneur

Yves Chauvin, 75 ans, est un ancien élève de l’École Supérieure de Chimie Physique Électronique de Lyon (promotion 1954). Directeur de Recherche à l’Institut Français du Pétrole, il fait preuve d’une créativité scientifique remarquable dans le domaine de la catalyse homogène. Il est à l’heure actuelle Directeur de Recherche Émérite à l’UMR 9986 à Lyon (France).Richard R. Schrock, 60 ans, obtient son PhD à Harvard (États-Unis) en 1971 sous la direction de J.A. Osborn. Après un séjour post-doctoral avec Jack Lewis à Cambridge et un début de carrière chez duPont de Nemours, il est nommé professeur au Massachussetts Institute of Technology (MIT) à Cambridge (États-Unis) en 1980.Robert H. Grubbs, 63 ans, obtient son PhD à l’Université de Columbia (New York, États-Unis). Après un séjour postdoctoral à Stanford (California, États-Unis) sous la direction de Jim Collman, il rejoint en 1978 le California Institute of Technology (Caltech, Pasadena, États-Unis) où il est à l’heure actuelle professeur de chimie

On processes which are infinitely divisible with respect to time

The aim of this short note is to present the notion of IDT processes, which is a wide generalization of L\'{e}vy processes obtained from a modified infinitely divisible property. Special attention is put on a number of examples, in order to clarify how much the IDT processes either differ from, or resemble to, L\'{e}vy processes

Antidepressant therapy with milnacipran and venlafaxine

Specific serotonin norepinephrine reuptake inhibitors (SNRIs) have been described as “better tolerated tricyclic antidepressants” or as “boosted” selective serotonin reuptake inhibitors (SSRIs). Venlafaxine has become a therapeutic reference treatment for major depression. Although less widely studied, indirect comparisons with another SNRI, milnacipran, suggest an equivalent efficacy. This paper discusses these indirect comparisons and the recently published first double-blind, head-to-head comparison. Venlafaxine has potency at serotonin transporters which is about 30-fold greater than that at norepinephrine transporters while milnacipran has a similar potency at each transporter. Thus, at low doses, venlafaxine acts essentially as a SSRI, with significant noradrenergic activity only occurring at higher doses. To overcome the problem of the differing profile of venlafaxine at increasing doses, the first head-to-head study compared the therapeutic effects and tolerability of the two antidepressants when flexibly titrated to the high dose of 200 mg/day. The study showed that the two SNRIs have similar efficacy and safety profiles. Both drugs produced about 42% remissions at the end of the 20-week study. The most frequent adverse events in both groups were nausea, dizziness, headache, and sweating. Certain specific differences in tolerability are discussed